Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

PDGF-BB serum levels are decreased in adult onset Pompe patients

  • Fernández Simón, Esther|||0000-0003-4804-6553
  • Carrasco-Rozas, Ana|||0000-0003-2165-8162
  • Gallardo, Eduard|||0000-0002-3942-3436
  • Figueroa-Bonaparte, Sebastian|||0000-0002-6546-1321
  • Belmonte Jimeno, Izaskun|||0000-0003-0930-6586
  • Pedrosa Hernández, Irene
  • Montiel Morillo, Elena
  • Suárez Calvet, Xavier|||0000-0002-5314-6607
  • Alonso Pérez, Jorge|||0000-0001-8866-5186
  • Nuñez Peralta, Claudia Alejandra|||0000-0002-3235-0799
  • Llauger, Jaume|||0000-0002-3744-3257
  • Mayos, Merce|||0000-0003-3972-3671
  • Illa, Isabel|||0000-0002-2186-2684
  • Barba Romero, Miguel Ángel|||0000-0001-5076-607X
  • Barcena, Joseba
  • Carzorla, María Rosario
  • Creus, Carlota
  • Coll-Cantí, Jaume|||0000-0001-7128-1186
  • Luna Salva, Noemí de|||0000-0002-4342-794X
  • Díaz, Manuel
  • Domínguez-González, Cristina|||0000-0001-5151-988X
  • Fernandez-Torron, Roberto|||0000-0002-2202-8165
  • García-Antelo, María José
  • Grau, Josep M.|||0000-0001-7560-224X
  • Gómez-Caravaca, María Teresa
  • León-Hernández, Juan Carlos
  • López de Munáin, Adolfo
  • Martínez-García, Francisco Antonio
  • Morgado, Yolanda
  • Moreno Camacho, Asunción|||0000-0001-6382-0039
  • Morís, Germán|||0000-0001-7608-2194
  • Muñoz-Blanco, Miguel Angel
  • Nascimento, Andres
  • Paradas, Carmen|||0000-0002-6917-2236
  • Parajuá-Pozo, José Luis
  • Querol, Luis|||0000-0002-4289-8264
  • Robledo-Strauss, Arturo
  • Rojas-Garcia, Ricard|||0000-0003-1411-5573
  • Rojas-Marcos, Íñigo
  • Salazar, Jose Antonio
  • Usón, Mercedes
  • Diaz-Manera, Jordi|||0000-0003-2941-7988
Adult onset Pompe disease is a genetic disorder characterized by slowly progressive skeletal and respiratory muscle weakness. Symptomatic patients are treated with enzymatic replacement therapy with human recombinant alfa glucosidase. Motor functional tests and spirometry are commonly used to follow patients up. However, a serological biomarker that correlates with the progression of the disease could improve follow-up. We studied serum concentrations of TGFβ, PDGF-BB, PDGF-AA and CTGF growth factors in 37 adult onset Pompe patients and 45 controls. Moreover, all patients performed several muscle function tests, conventional spirometry, and quantitative muscle MRI using 3-point Dixon. We observed a statistically significant change in the serum concentration of each growth factor in patients compared to controls. However, only PDGF-BB levels were able to differentiate between asymptomatic and symptomatic patients, suggesting its potential role in the follow-up of asymptomatic patients. Moreover, our results point to a dysregulation of muscle regeneration as an additional pathomechanism of Pompe disease.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Nintedanib decreases muscle fibrosis and improves muscle function in a murine model of dystrophinopathy

  • Piñol-Jurado, Patricia|||0000-0002-2757-5758
  • Suarez-Calvet, Xavier|||0000-0002-5314-6607
  • Fernández Simón, Esther|||0000-0003-4804-6553
  • Gallardo, Eduard|||0000-0002-3942-3436
  • de la Oliva, Natalia|||0000-0002-1263-2705
  • Martínez-Muriana, Anna
  • Gómez-Gálvez, Pedro
  • Escudero, Luis M.
  • Pérez-Peiró, María|||0000-0001-9375-8416
  • Wollin, Lutz|||0000-0002-3617-5772
  • Luna Salva, Noemí de|||0000-0002-4342-794X
  • Navarro, X. (Xavier)|||0000-0001-9849-902X
  • Illa, Isabel|||0000-0002-2186-2684
  • Diaz-Manera, Jordi|||0000-0003-2941-7988
Duchenne muscle dystrophy (DMD) is a genetic disorder characterized by progressive skeletal muscle weakness. Dystrophin deficiency induces instability of the sarcolemma during muscle contraction that leads to muscle necrosis and replacement of muscle by fibro-adipose tissue. Several therapies have been developed to counteract the fibrotic process. We report the effects of nintedanib, a tyrosine kinase inhibitor, in the mdx murine model of DMD. Nintedanib reduced proliferation and migration of human fibroblasts in vitro and decreased the expression of fibrotic genes such as COL1A1, COL3A1, FN1, TGFB1, and PDGFA. We treated seven mdx mice with 60 mg/kg/day nintedanib for 1 month. Electrophysiological studies showed an increase in the amplitude of the motor action potentials and an improvement of the morphology of motor unit potentials in the animals treated. Histological studies demonstrated a significant reduction of the fibrotic areas present in the skeletal muscles. Analysis of mRNA expression from muscles of treated mice showed a reduction in Col1a1, Col3a1, Tgfb1, and Pdgfa. Western blot showed a reduction in the expression of collagen I in skeletal muscles. In conclusion, nintedanib reduced the fibrotic process in a murine model of dystrophinopathy after 1 month of treatment, suggesting its potential use as a therapeutic drug in DMD patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Quantitative muscle MRI to follow up late onset Pompe patients, a prospective study

  • Figueroa-Bonaparte, Sebastian|||0000-0002-6546-1321
  • Llauger, Jaume|||0000-0002-3744-3257
  • Segovia, Sonia
  • Belmonte Jimeno, Izaskun|||0000-0003-0930-6586
  • Pedrosa Hernández, Irene
  • Montiel Morillo, Elena
  • Montesinos, Paula|||0000-0001-6944-7730
  • Sánchez González, Javier|||0000-0003-1427-3870
  • Alonso-Jiménez, Alicia|||0000-0002-2200-9255
  • Gallardo, Eduard|||0000-0002-3942-3436
  • Illa, Isabel|||0000-0002-2186-2684
  • Diaz-Manera, Jordi|||0000-0003-2941-7988
Late onset Pompe disease (LOPD) is a slow, progressive disorder characterized by skeletal and respiratory muscle weakness. Enzyme replacement therapy (ERT) slows down the progression of muscle symptoms. Reliable biomarkers are needed to follow up ERT-treated and asymptomatic LOPD patients in clinical practice. In this study, 32 LOPD patients (22 symptomatic and 10 asymptomatic) underwent muscle MRI using 3-point Dixon and were evaluated at the time of the MRI with several motor function tests and patient-reported outcome measures, and again after one year. Muscle MRI showed a significant increase of 1.7% in the fat content of the thigh muscles in symptomatic LOPD patients. In contrast, there were no noteworthy differences between muscle function tests in the same period of time. We did not observe any significant changes either in muscle MRI or in muscle function tests in asymptomatic patients over the year. We conclude that 3-point Dixon muscle MRI is a useful tool for detecting changes in muscle structure in symptomatic LOPD patients and could become part of the current follow-up protocol in daily clinics.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Muscle MRI Findings in Childhood/Adult Onset Pompe Disease Correlate with Muscle Function

  • Figueroa-Bonaparte, Sebastian|||0000-0002-6546-1321
  • Segovia, Sonia
  • Llauger, Jaume|||0000-0002-3744-3257
  • Belmonte Jimeno, Izaskun|||0000-0003-0930-6586
  • Pedrosa Hernández, Irene
  • Alejaldre, Aída|||0000-0003-3501-2637
  • Mayos, Merce|||0000-0003-3972-3671
  • Suarez Cuartin, Guillermo|||0000-0003-2320-6047
  • Gallardo, Eduard|||0000-0002-3942-3436
  • Illa, Isabel|||0000-0002-2186-2684
  • Diaz-Manera, Jordi|||0000-0003-2941-7988
Enzyme replacement therapy has shown to be effective for childhood/adult onset Pompe disease (AOPD). The discovery of biomarkers useful for monitoring disease progression is one of the priority research topics in Pompe disease. Muscle MRI could be one possible test but the correlation between muscle MRI and muscle strength and function has been only partially addressed so far. We studied 34 AOPD patients using functional scales (Manual Research Council scale, hand held myometry, 6 minutes walking test, timed to up and go test, time to climb up and down 4 steps, time to walk 10 meters and Motor Function Measure 20 Scale), respiratory tests (Forced Vital Capacity seated and lying, Maximun Inspiratory Pressure and Maximum Expiratory Pressure), daily live activities scales (Activlim) and quality of life scales (Short Form-36 and Individualized Neuromuscular Quality of Life questionnaire). We performed a whole body muscle MRI using T1w and 3-point Dixon imaging centered on thighs and lower trunk region. T1w whole body muscle MRI showed a homogeneous pattern of muscle involvement that could also be found in pre-symptomatic individuals. We found a strong correlation between muscle strength, muscle functional scales and the degree of muscle fatty replacement in muscle MRI analyzed using T1w and 3-point Dixon imaging studies. Moreover, muscle MRI detected mild degree of fatty replacement in paraspinal muscles in pre-symptomatic patients. Based on our findings, we consider that muscle MRI correlates with muscle function in patients with AOPD and could be useful for diagnosis and follow-up in pre-symptomatic and symptomatic patients under treatment. Muscle MRI correlates with muscle function in patients with AOPD and could be useful to follow-up patients in daily clinic.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Transcriptome Analysis of Ullrich Congenital Muscular Dystrophy Fibroblasts Reveals a Disease Extracellular Matrix Signature and Key Molecular Regulators

  • Paco Mercader, Sonia|||0000-0002-7151-8144
  • Casserras, Teresa
  • Rodríguez, Maria Angels
  • Jou, Cristina|||0000-0002-2223-7880
  • Puigdelloses, Montserrat
  • Ortez González, Carlos Ignacio|||0000-0001-8187-8103
  • Diaz-Manera, Jordi|||0000-0003-2941-7988
  • Gallardo, Eduard|||0000-0002-3942-3436
  • Colomer, Jaume
  • Nascimento, Andrés
  • Kalko, Susana G.|||0000-0002-6701-0233
  • Jiménez Mallebrera, Cecilia|||0000-0001-8203-7103
Collagen VI related myopathies encompass a range of phenotypes with involvement of skeletal muscle, skin and other connective tissues. They represent a severe and relatively common form of congenital disease for which there is no treatment. Collagen VI in skeletal muscle and skin is produced by fibroblasts. In order to gain insight into the consequences of collagen VI mutations and identify key disease pathways we performed global gene expression analysis of dermal fibroblasts from patients with Ullrich Congenital Muscular Dystrophy with and without vitamin C treatment. The expression data were integrated using a range of systems biology tools. Results were validated by real-time PCR, western blotting and functional assays. We found significant changes in the expression levels of almost 600 genes between collagen VI deficient and control fibroblasts. Highly regulated genes included extracellular matrix components and surface receptors, including integrins, indicating a shift in the interaction between the cell and its environment. This was accompanied by a significant increase in fibroblasts adhesion to laminin. The observed changes in gene expression profiling may be under the control of two miRNAs, miR-30c and miR-181a, which we found elevated in tissue and serum from patients and which could represent novel biomarkers for muscular dystrophy. Finally, the response to vitamin C of collagen VI mutated fibroblasts significantly differed from healthy fibroblasts. Vitamin C treatment was able to revert the expression of some key genes to levels found in control cells raising the possibility of a beneficial effect of vitamin C as a modulator of some of the pathological aspects of collagen VI related diseases.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Platelet Derived Growth Factor-AA Correlates With Muscle Function Tests and Quantitative Muscle Magnetic Resonance in Dystrophinopathies

  • Alonso-Jiménez, Alicia|||0000-0002-2200-9255
  • Fernández Simón, Esther|||0000-0003-4804-6553
  • Natera-de Benito, Daniel|||0000-0001-7764-2085
  • Ortez González, Carlos Ignacio|||0000-0001-8187-8103
  • García, Carme
  • Montiel Morillo, Elena
  • Belmonte Jimeno, Izaskun|||0000-0003-0930-6586
  • Pedrosa Hernández, Irene
  • Segovia, Sonia
  • Piñol-Jurado, Patricia|||0000-0002-2757-5758
  • Carrasco-Rozas, Ana|||0000-0003-2165-8162
  • Suárez Calvet, Xavier|||0000-0002-5314-6607
  • Jiménez Mallebrera, Cecilia|||0000-0001-8203-7103
  • Nascimento, Andrés
  • Llauger, Jaume|||0000-0002-3744-3257
  • Nuñez Peralta, Claudia Alejandra|||0000-0002-3235-0799
  • Montesinos, Paula|||0000-0001-6944-7730
  • Alonso Pérez, Jorge|||0000-0001-8866-5186
  • Gallardo, Eduard|||0000-0002-3942-3436
  • Illa, Isabel|||0000-0002-2186-2684
  • Diaz-Manera, Jordi|||0000-0003-2941-7988
Introduction: Duchenne (DMD) and Becker (BMD) muscular dystrophy are X-linked muscular disorders produced by mutations in the DMD gene which encodes the protein dystrophin. Both diseases are characterized by progressive involvement of skeletal, cardiac, and respiratory muscles. As new treatment strategies become available, reliable biomarkers and outcome measures that can monitor disease progression are needed for clinical trials. Methods: We collected clinical and functional data and blood samples from 19 DMD patients, 13 BMD patients, and 66 healthy controls (8 pediatric and 58 adult controls), and blood samples from 15 patients with dysferlinopathy (DYSF) and studied the serum concentration of 4 growth factors involved in the process of muscle fibrosis. We correlated the serum concentration of these growth factors with several muscle function tests, spirometry results and fat fraction identified by quantitative Dixon muscle MRI. Results: We found significant differences in the serum concentration of Platelet Derived Growth Factor-AA (PDGF-AA) between DMD patients and pediatric controls, in Connective Tissue Growth Factor (CTGF) between BMD patients and adult controls, and in and Transforming Growth Factor- β1 (TGF-β1) between BMD and DYSF patients. PDGF-AA showed a good correlation with several muscle function tests for both DMD and BMD patients and with thigh fat fraction in BMD patients. Moreover, PDGF-AA levels were increased in muscle biopsies of patients with DMD and BMD as was demonstrated by immunohistochemistry and Real-Time PCR studies. Conclusion: Our study suggests that PDGF-AA should be further investigated in a larger cohort of DMD and BMD patients because it might be a good biomarker candidate to monitor the progression of these diseases.